Background: Restriction is a typical functional abnormality in interstitial lung disease (ILD) patients, but is not always present, especially in the early stage of the disease. The greater reduction of vital capacity (VC; %pred.) than total lung capacity (TLC; %pred.) is regarded as a typical pattern of lung function disturbances in ILD patients. Study Objectives: To explore the diagnostic value of spirometry in a detection restrictive pattern the relative volume loss assessed by TLC and VC in large series of patients with a diagnosis of ILD referred for lung function tests was evaluated. Methods: Retrospective, cross-sectional analysis of pulmonary function data was done. The sampleconsisted of 1,173 patients with the diagnosis of different interstitial lung diseases investigated during a period of 5 years. Only patients without airway obstruction (normal FEV1%VC) were included. In all cases spirometry and whole body plethysmography were performed by experienced staff using MasterLab – ‘Jaeger’ equipment according to ERS standards. Reference values according to ERS guidelines were applied. Results: The mean value of TLC expressed as %pred. was significantly (p < 0.001) lower than VC in all patients (93.7 ± 18.6 vs. 98.0 ± 21.4%pred.). The frequency of abnormal (lowered) TLC results was also higher than lowered VC (22.8 vs. 17.8%). Sensitivity of VC reached 69.3% and the positive predictive value was 88.5% in detecting volume restriction as compared to TLC measurement. Conclusion: The relative loss of TLC was greater than VC in our large group of patients. Measurement of TLC should be part of functional assessment of ILD patients, irrespective of whether they present or do not present a restrictive pattern in spirometry.

Keywords:
Pulmonary function tests, Spirometry, Interstitial lung diseases, Lung volumes, Diagnosis
1.
Schwarz MI, King TE Jr, Raghu G: Approach to the evaluation and diagnosis of interstitial lung disease; in Schwarz MI, King TE Jr (eds): Interstitial Lung Disease. Hamilton, Decker, 2003, pp 1–30.
2.
O’Donnell DE, Fitzpatrick MF: Physiology of interstitial lung disease; in Schwarz MI, King TE Jr (eds): Interstitial Lung Disease. Hamilton, Decker, 2003, pp 54–74.
3.
Gottlieb DJ, Snider GL: Lung function in pulmonary fibrosis; in Phan SH, Thrall RS (eds): Pulmonary Fibrosis. New York, Dekker, 1995, pp 85–133.
4.
Cherniack RM, Colby TV, Flint A, Thurlbeck WM, Waldron JA Jr, Ackerson L, Schwarz MI, King TE Jr: Correlation of structure and function in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995;151:1180–1188.
5.
Doherty MJ, Pearson MG, O’Grady EA, Pellegrini V, Calverley PM: Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 1997;52:998–1002.
6.
Schwartz DA, Merchant RK, Helmers RA, Gilbert SR, Dayton CS, Hunninghake GW: The influence of cigarette smoking on lung function in patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991;144:504–506.
7.
Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:1–100.
8.
Stocks J, Quanjer PH: Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official Statement of the European Respiratory Society. Eur Respir J 1995;8:492–506.
9.
Guidelines for the measurement of respiratory function. Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Respir Med 1994;88:165–194.
10.
Chung MP, Rhee CH: Airway obstruction in interstitial lung disease. Curr Opin Pulm Med 1997;3:332–335.
11.
Dutton RE, Renzi PM, Lopez-Majano V, Renzi GD: Airway function in sarcoidosis: Smokers versus nonsmokers. Respiration 1982;43:164–173.
12.
Hanley ME, King TE, Schwarz MI, Watters LC, Shen AS, Cherniack RM: The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. Am Rev Respir Dis 1991;144:1102–1106.
13.
Aaron SD, Dales RE, Cardinal P: How accurate is spirometry at predicting restrictive pulmonary impairment? Chest 1999;115:869–873.
14.
Carrington CB: Structure and function in sarcoidosis. Ann NY Acad Sci 1976;278:265–283.
15.
De Troyer A, Yernault JC, Dierckx P, Englert M, De Coster A: Lung and airway mechanics in early pulmonary sarcoidosis. Bull Physiopathol Respir (Nancy) 1979;14:299–310.
16.
Westall GP, Stirling RG, Cullinan P, du Bois RM: Sarcoidosis; in Schwarz MI, King TE Jr (eds): Interstitial Lung Disease. Hamilton, Decker, 2003, pp 332–386.
17.
Jodoin G, Gibbs GW, Macklem PT, McDonald JC, Becklake MR: Early effects of asbestos exposure on lung function. Am Rev Respir Dis 1971;104:525–535.
18.
Boros P, Radwan L, Kowalski J: Sensitivity of static lung compliance (Cst) and diffusion lung capacity (DLco) as markers of lung function impairment in non-restrictive interstitial lung disease (ILD) patients. Eur Respir J 2000;16(suppl 31):572s.
19.
Boros P, Radwan L, Kowalski J: Static lung compliance (Cst) and diffusion lung capacity (DLco) as markers of lung function impairment in large group of non-restrictive interstitial lung disease (ILD) patients. Am J Respir Crit Care Med 2002;165(suppl 8):A139.
20.
Wesolowski S, Boros P, Kus J, Oniszh K, Langfort R: Lung volumes, diffusing capacity and static lung compliance in patients with UIP pattern of IPF. Eur Respir J 2002;20(suppl 38):62s.
21.
Erbes R, Schaberg T, Loddenkemper R: Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest 1997;111:51–57.
22.
Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP: Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199–203.
23.
Daniil ZD, Gilchrist FC, Nicholson AG, Hansell DM, Harris J, Colby TV, du Bois RM: A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999;160:899–905.
24.
Johnston ID, Prescott RJ, Chalmers JC, Rudd RM: British Thoracic Society study of cryptogenic fibrosing alveolitis: Current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax 1997;52:38–44.
25.
Gibson GJ, Pride NB, Davis JN, Loh LC: Pulmonary mechanics in patients with respiratory muscle weakness. Am Rev Respir Dis 1977;115:389–395.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.